A Phase 1b Study of JNJ-80948543 in Combination with Other CD3 TCEs for R/R B-cell NHL
80948543LYM1002
Phase 1 other active
Quick answer
A Phase 1b Study of JNJ-80948543 in Combination with Other CD3 TCEs for R/R B-cell NHL for Relapsed/Refractory B-cell Non-Hodgkin Lymphoid Malignancies is a Phase 1 program (other) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen-Cilag International N.V.
- Indication
- Relapsed/Refractory B-cell Non-Hodgkin Lymphoid Malignancies
- Phase
- Phase 1
- Modality
- other
- Status
- active